BioArctic´s patents on an Alzheimer transgenic model have been granted in the US and in Australia.
Alzheimer’s disease is the most common dementia disorder and currently there are no treatments that can stop the disease progress. BioArctic has developed a new proprietary transgenic mouse model for evaluation of Alzheimer drugs.
A human gene with the Arctic and Swedish mutations has been engineered into the model resulting in a rapid pathology, with visible plaques within 5-6 months and intracellular Aß accumulation within 1-2 months. Hence, the model provides a rapid and powerful new tool for drug efficacy and screening studies, suitable for drugs acting early in the disease process.